Payment overview · 2025
General Payments
$453.18
17 reported records · 11 companies
Healthcare provider profile · identity verified
Leslie Mcgraw, APN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · YERINGTON, NV · NPI 1922074335
Verified facts
What the public records show
CMS Open Payments records show Leslie Mcgraw, APN received $453.18 in general payments during 2025 across 17 reported records.
GENZYME CORPORATION accounted for 31.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Trelegy Ellipta, Veozah.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Veozah as an associated drug or biological on 82795 records involving 35863 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Veozah by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $140.59 | 31.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $57.49 | 12.7% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $56.19 | 12.4% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $48.47 | 10.7% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $35.96 | 7.9% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $27.18 | 6.0% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $22.35 | 4.9% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $19.94 | 4.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.55 | 3.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.09 | 3.3% | 1 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $14.37 | 3.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $453.18 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $140.59 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $57.49 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $57.49 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $57.49 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $56.19 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $48.47 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $27.18 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $22.35 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $19.94 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $19.94 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $19.25 | 1 | 2025 |
Source payment records
|
|||||
| MENVEO Normalized: menveo |
Biological | GlaxoSmithKline, LLC. | $19.25 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.71 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.71 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.55 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.55 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.09 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.09 | 1 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $14.37 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $14.37 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Veozah veozah |
2025 | Veozah | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
76 | 18 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Veozah open payments reported associated product |
CMS Open Payments — General Payments 82795 supporting records · 35863 recipient NPIs · example record 1238560678 |
Veozah · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
88 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
93 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lisinopril | Lisinopril | 422 | 116 |
| Levothyroxine Sodium | Levothyroxine Sodium | 414 | 108 |
| Atorvastatin Calcium | Atorvastatin Calcium | 326 | 91 |
| Amlodipine Besylate | Amlodipine Besylate | 259 | 79 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 252 | 75 |
| Losartan Potassium | Losartan Potassium | 230 | 66 |
| Gabapentin | Gabapentin | 226 | 65 |
| Trazodone Hcl | Trazodone Hcl | 185 | 46 |
| Omeprazole | Omeprazole | 166 | 61 |
| Sertraline Hcl | Sertraline Hcl | 160 | 46 |
| Simvastatin | Simvastatin | 132 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 103 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 102 | 46 |
| Furosemide | Furosemide | 100 | 25 |
| Carvedilol | Carvedilol | 98 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 96 | 33 |
| Tramadol Hcl | Tramadol Hcl | 96 | 12 |
| Eliquis | Apixaban | 93 | 24 |
| Montelukast Sodium | Montelukast Sodium | 91 | 29 |
| Alprazolam | Alprazolam | 89 | 20 |
| Jardiance | Empagliflozin | 88 | 21 |
| Metformin Hcl | Metformin Hcl | 80 | 24 |
| Synthroid | Levothyroxine Sodium | 76 | 18 |
| Baclofen | Baclofen | 74 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 74 | 22 |
| Potassium Chloride | Potassium Chloride | 74 | 21 |
| Telmisartan | Telmisartan | 73 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 70 | 24 |
| Meloxicam | Meloxicam | 68 | 28 |
| Breo Ellipta | Fluticasone/Vilanterol | 65 | 11 |
| Lovastatin | Lovastatin | 60 | 18 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 59 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 58 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 58 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 57 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 57 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 54 | 39 |
| Azithromycin | Azithromycin | 54 | 24 |
| Celecoxib | Celecoxib | 52 | 20 |
| Metformin Hcl Er | Metformin Hcl | 52 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 51 | 16 |
| Allopurinol | Allopurinol | 50 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 49 | 11 |
| Lorazepam | Lorazepam | 48 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 46 | 14 |
| Donepezil Hcl | Donepezil Hcl | 45 | 13 |
| Ipratropium Bromide | Ipratropium Bromide | 45 | suppressed |
| Prednisone | Prednisone | 45 | 16 |
| Bupropion Hcl Sr | Bupropion Hcl | 43 | 16 |
| Buspirone Hcl | Buspirone Hcl | 43 | 17 |
| Temazepam | Temazepam | 43 | suppressed |
| Estradiol | Estradiol | 39 | 15 |
| Acyclovir | Acyclovir | 36 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 35 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 34 | suppressed |
| Mounjaro | Tirzepatide | 34 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 33 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 15 |
| Famotidine | Famotidine | 31 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 29 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Ozempic | Semaglutide | 28 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Ibuprofen | Ibuprofen | 27 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 26 | 11 |
| Glipizide | Glipizide | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Methocarbamol | Methocarbamol | 24 | suppressed |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 23 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Atenolol | Atenolol | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 19 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 18 |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Methylprednisolone | Methylprednisolone | 18 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 12 |
| Cephalexin | Cephalexin | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Ezetimibe | Ezetimibe | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Veozah | Fezolinetant | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $453.18 · 17 records | GENZYME CORPORATION | ABRYSVO, AREXVY, BEXSERO, CAPVAXIVE, COMIRNATY, DUPIXENT, Flexitouch Plus, GARDASIL 9, GEMTESA, LEQVIO, MENVEO, MOUNJARO, Nimbl, OTEZLA, PREVNAR 20, REPATHA, TRELEGY ELLIPTA, VRAYLAR, Veozah, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error